Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122669 | 0.84 | HTR2A (0.43) | MTNR1AMTNR1BADRA1ATAAR1 | |
| SCHEMBL6487286 | 0.83 | ADRA1A (0.41) | MTNR1AMTNR1BADRA1ATAAR1AOC3 | |
| SCHEMBL15413855 | 0.82 | SLC6A4 (0.54) | ADRA1ATAAR1SLC6A2SLC6A4 | |
| SCHEMBL3360173 | 0.81 | ADRA1A (0.40) | MTNR1AMTNR1BADRA1ATAAR1AOC3 | |
| SCHEMBL30669668 | 0.81 | SLC6A2 (0.51) | TNKS2MTNR1AMTNR1BADRA1ATAAR1 | |
| SCHEMBL29138541 | 0.81 | SLC6A2 (0.51) | TNKS2MTNR1AMTNR1BADRA1ATAAR1 | |
| SCHEMBL5833761 | 0.81 | ADRA1A (0.64) | MTNR1AMTNR1BADRA1ATAAR1AOC3 | |
| SCHEMBL7782798 | 0.80 | GABRA1 (0.48) | ADRA1ATAAR1AOC3 | |
| SCHEMBL13845938 | 0.80 | ADRA1A (0.39) | MTNR1AMTNR1BADRA1ATAAR1SLC6A2 | |
| SCHEMBL13845991 | 0.80 | ADRA1A (0.39) | MTNR1AMTNR1BADRA1ATAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | TNKS2 827/4885MTNR1A 2793/4885MTNR1B 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.